Janus Henderson Global Life Sciences benefits from an exceptional lead manager, strong support resources, and a consistently applied robust investment process with prudent risk management, underpinning its Above Average People and Process Pillar ratings.
Janus Henderson Global Life Sciences Fund Class N JFNNX
- NAV / 1-Day Return 86.74 / −1.51 %
- Total Assets 5.8B
-
Adj. Expense Ratio
0.680%
- Expense Ratio 0.680%
- Distribution Fee Level Below Average
- Share Class Type Institutional
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 1M
- Status Open
- TTM Yield 0.48%
- Turnover 30%
USD | NAV as of Jul 21, 2026 | 1-Day Return as of Jul 21, 2026, 12:11 AM GMT+0
Morningstar’s Analysis JFNNX
Will JFNNX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 41.4
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 8.86 | 467M | Healthcare |
Johnson & Johnson | 6.92 | 364M | Healthcare |
AstraZeneca PLC | 4.39 | 231M | Healthcare |
UnitedHealth Group Inc | 4.30 | 227M | Healthcare |
AbbVie Inc | 3.92 | 207M | Healthcare |
Revolution Medicines Inc Ordinary Shares | 2.96 | 156M | Healthcare |
Novartis AG ADR | 2.71 | 143M | Healthcare |
argenx SE ADR | 2.51 | 132M | Healthcare |
Thermo Fisher Scientific Inc | 2.42 | 127M | Healthcare |
Praxis Precision Medicines Inc Ordinary Shares | 2.35 | 124M | Healthcare |